Procter & Gamble Co.

Adds consumer product, brand, and operational leadership experience to support commercialization of the VetBreath Analytics platform Global Innovative Platforms Inc (OTCMKTS:GIPL) David has a strong track record in product strategy brand development and operational execution” — Andrew Brown, CEO ORLANDO, FL, UNITED STATES, April 21, 2026 / EINPresswire.com / -- Global Innovative Platforms Inc. (OTC: GIPL), a reporting company under the Securities Exchange Act of 1934 focused on advancing non-invasive diagnostics in animal health , today announced the appointment of David M. Mauer to its Board of Directors, effective April 1, 2026. Mr. Mauer brings extensive experience in consumer product management, brand development, and operational leadership across both public and private companies. His appointment is intended to support the Company’s commercialization strategy as it advances development of its VetBreath Analytics platform . Andrew Brown, Chief Executive Officer of Global Innovative Platforms, stated, “David has led organizations at scale and has a strong track record in product strategy, brand development, and operational execution. His experience will be valuable as we continue to develop our commercialization approach and expand our market presence.” David M. Mauer – Board of Directors David M. Mauer is the former President of Mattel U.S.A. and former Chief Executive Officer of Riddell Sports, with a multi-decade career in global consumer products, marketing, and operational leadership. He began his career at Procter & Gamble and later held marketing leadership roles at PepsiCo, focusing on brand strategy and product positioning. He joined Kenner Products in 1981, serving as Executive Vice President of Marketing and Product Development and later as President. Following Kenner’s acquisition by Tonka, Mr. Mauer became President of the Tonka U.S. Toy Group, overseeing U.S. operations and global manufacturing. As President of Mattel U.S.A., he was responsible for worldwide product development as well as domestic sales and marketing, where he led operational improvements and supported cash flow performance. As Chief Executive Officer of Riddell Sports, Mr. Mauer expanded the company’s market reach, introduced a direct-to-institution sales model, and led the acquisition of Varsity Spirit. He later served as Chief Executive Officer of EB Brands, where he transitioned the company from a founder-led organization to a more structured operating model. Mr. Mauer is currently the founder of University Place Partners, where he provides marketing and product strategy advisory services to emerging companies. He has also served on multiple corporate boards, including The Topps Company and Skip Hop. Strategic Relevance to Global Innovative Platforms Global Innovative Platforms is developing the VetBreath Analytics platform, a non-invasive diagnostic approach designed to detect disease-associated volatile organic compound patterns in animal breath. The platform is initially focused on heartworm detection in dogs, with ongoing development of additional parasite markers and future expansion into broader animal health applications. As the Company progresses toward commercialization, experience in product positioning, market development, and operational scaling is important to support adoption across veterinary practices. Mr. Mauer’s background in consumer product strategy and organizational leadership is expected to support these efforts. About Global Innovative Platforms Inc. Global Innovative Platforms Inc. (OTC: GIPL) is a reporting company under the Securities Exchange Act of 1934 focused on developing and commercializing non-invasive diagnostic technologies for animal health. Its VetBreath Analytics platform is designed to analyze volatile organic compounds in exhaled breath to identify disease-associated patterns, with an initial focus on heartworm and intestinal parasite detection in dogs. The Company is advancing research, validation studies, and commercialization initiatives to support broader adoption across veterinary practices. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, expectations regarding the Company’s strategic initiatives, development and commercialization of its VetBreath Analytics platform for non-invasive breath-based diagnostics in animal health (with an initial focus on parasite detection such as heartworm in dogs), potential revenue growth, and use of proceeds from any financing activities. Forward-looking statements are generally identified by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,” “forecast,” “predict,” and similar expressions, or by statements that events or trends “may,” “will,” or “could” occur. These forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including but not limited to: the early-stage nature of the Company’s technology and limited operating history; dependence on successful further development, testing, and potential regulatory clearance or commercialization of the VetBreath Analytics platform; ability to generate meaningful revenue and achieve profitability; need for additional financing to fund operations and development; competition in the animal health diagnostics market; technological, intellectual property, or execution risks; general economic and market conditions; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission, including the most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release and in the Company's SEC filings. Global Innovative Platforms Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Investors are cautioned not to place undue reliance on these forward-looking statements. Roger Hayes Global Innovative Platforms Inc. +1 502-271-8444 email us here Visit us on social media: LinkedIn YouTube VetBreath Analytics Featured on Animal Health Today Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Round positions Omeza to accelerate clinical development and scale nationwide commercialization of its FDA-cleared regenerative wound care platform Sarasota, FL - April 21 sh , 2026 - Omeza Holdings, Inc. (“Omeza”), a commercial-stage advanced wound care company with an FDA-cleared regenerative product already marketed in the U.S., today announced the closing of an $8.5 million Series A financing round co-led by Astanor and BluKap Ventures, with participation from Catalyst Investments and historical investors including the Florida Opportunity Fund. Omeza is already generating revenue through a nationwide commercial partnership and is advancing clinical programs to expand reimbursement across major hard-to-heal wounds. The round reflects growing institutional conviction in Omeza’s differentiated clinical and commercial platform. Proceeds will be used to accelerate clinical trials, expand commercial capabilities, and strengthen the company’s clinical and real-world evidence base to support broader reimbursement coverage. Advanced wound care represents a multi-billion-dollar market in the United States alone, with significant unmet need for cost-effective, scalable therapies. Board appointments Concurrent with the closing, Omeza’s Board of Directors has been strengthened with the appointment of: Henry Gazay Co-founder & Managing Partner BluKap Ventures Non-executive Director Edouard Cukierman Founder & Managing Partner Catalyst Investments Non-executive Director Eric Archambeau Founder and Managing Partner Astanor Board Observer These appointments reflect the company’s transition toward institutional governance and its next phase of growth. Henry Gazay brings over 30 years of entrepreneurial and investment experience in South Florida and an extensive international network across the Americas, Europe and Asia in healthcare and life sciences. Edouard Cukierman brings over 30 years of cross-border investment expertise spanning the Middle East, Europe, the United States, and Asia, and a proven track record of building governance structures for high-growth technology and life science companies. Astanor will be represented as a Board Observer. Company and Product Omeza’s lead product, OCM™, is an FDA-cleared drug-device wound matrix derived from marine lipids and cold water fish peptides. Applied in various settings, it reduces inflammation, disrupts bacterial biofilm, and supports tissue regeneration, offering a highly effective and cost-efficient alternative to traditional skin grafts. Leadership and Investor Commentary “This financing marks a pivotal milestone for Omeza as we advance our clinical development and accelerate our commercial strategy. The caliber and diversity of our Board underscore the strength of the investor syndicate we have assembled. Henry contributes deep global healthcare investor relationships and strategic perspective, Edouard brings a proven track record of scaling technology and life science companies across multiple markets, and Eric’s role as board observer adds the insight of one of Europe’s leading impact investors. Collectively, this positions Omeza with exceptional strength and clarity as we enter our next phase of growth. I would like to personally thank one of Omeza’s founding Board Directors, Alan George “A.G.” Lafley, for his outstanding service. A.G. Lafley is an American business leader, who served twice, as Procter & Gamble’s CEO, eventually retiring in 2016. As CEO, Lafley was called “one of the most lauded CEOs in history”. A.G. is also known as an expert in CEO succession, executive leadership development, and coaching experienced, new, and potential CEOs. His commitment to Omeza and his mentorship while working through the complexities of a start up company, have been invaluable. A.G. will retire from Omeza’s Board, and remains a significant shareholder in Omeza. We wish him well.” — Cynthia Flowers, Chief Executive Officer, Omeza “Omeza combines compelling clinical validation with a scalable commercial model addressing a large and underserved market. Its use of sustainably sourced, marine-derived biological compounds positions the company at the forefront of a new generation of regenerative wound care solutions. This strategy aligns closely with BluKap’s focus on translating ocean biodiversity into next-generation therapeutics. We are proud to lead this round alongside Astanor, Catalyst, and our co-investors, and to partner with Cynthia and the Omeza team as they scale a truly differentiated platform.” — Henry Gazay, Co-founder & Managing Partner, BluKap Ventures "Omeza strongly aligns with Astanor's investment thesis at the intersection of technology and nature, and our focus on nature-based solutions for human health. The company's use of sustainably sourced, marine-derived biological compounds in efficient wound care addresses the significant burden of chronic non-healing wounds, a condition that affects millions of patients, particularly older adults and those living with diabetes or vascular disease. This aligns directly with our impact thesis and our Article 9 commitment to investments that deliver measurable planetary and human health outcomes. We look forward to supporting Omeza's growth as it advances its clinical programs and builds a lasting platform in regenerative medicine." — Eric Archambeau, Founder & Senior Managing Partner, Astanor “Omeza exemplifies the kind of innovative, clinically grounded company that Catalyst seeks to support, one that combines a clear market need with a differentiated scientific approach and a strong management team. I am delighted to join the Board and to contribute to Omeza’s growth through Catalyst’s global network and cross-border investment expertise.” — Edouard Cukierman, Founder & Managing Partner, Catalyst Investments The Series A follows a broader effort to streamline Omeza’s capitalization table, align its investor base, and strengthen governance ahead of future institutional financing. The transaction also reflects the continued emergence of South Florida as a growing hub for life sciences and MedTech innovation, supported by a rapidly expanding ecosystem of investors, operators, and healthcare institutions. ABOUT OMEZA Omeza Holdings, Inc. is a U.S.-based advanced wound care company developing and commercializing marine-derived collagen and lipid products, with an FDA-cleared product already on the market and ongoing clinical programs to expand reimbursement and indications. Its lead product, OCM, incorporates sustainably sourced marine-derived biological compounds, including fish collagen, to accelerate healing in complex wounds, addressing a significant unmet medical need in the U.S. healthcare system. For more information, visit . ABOUT BLUKAP VENTURES BluKap Ventures is a global venture capital firm focused exclusively on ocean biotechnology. The firm backs companies developing next-generation therapeutics and technologies derived from ocean biodiversity, with a clear mission to unlock the medical value of sustainably sourced marine compounds. At the crossroads of human health and the blue economy, BluKap advances innovations that convert marine science into scalable, high-impact healthcare solutions. Founded by Henry Gazay and Jean-François Trecco, BluKap combines deep entrepreneurial and investment experience with a strong transatlantic network across healthcare, biotechnology, and marine science ecosystems. The firm provides portfolio companies with capital, strategic guidance, and access to a global network of investors, industry partners, and scientific experts. For more information, visit . ABOUT ASTANOR Astanor is a global impact investment firm with $1B in assets under management, backing seed through growth stage companies at the intersection of healthspan, nature, and physical AI. Founded in 2017, Astanor counts circa 50 investments to date in Europe, North America and beyond. The firm partners with visionary entrepreneurs and management teams building scalable solutions across agriculture, food production, and healthcare, applying robotics, AI, and nature-based science to advance human and planetary health. More information is available at . ABOUT CATALYST INVESTMENTS Catalyst Investments is an Israel-based private equity multi-fund firm with over 25 years of experience investing in high-growth technology and life science companies. Founded by Edouard Cukierman, Catalyst focuses on disruptive, internationally scalable companies with an Israel nexus across sectors including enterprise SaaS, cybersecurity, life sciences, climate tech, and smart mobility. The firm leverages a global network spanning the United States, Europe, Asia, and emerging markets to support portfolio companies with capital, strategic guidance, and cross-border expansion. Cukierman & Co. Investment House, the affiliated investment bank, has been engaged in over $10.8 billion of corporate finance transactions since its establishment in 1993. For more information, visit . Media contact Cynthia Flowers - CEO Omeza Holdings cflowers@omeza.com Henry Gazay - Co-founder BluKap ventures hgazay@blukap.vc Forward-looking statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to Omeza’s clinical development programs, commercial strategy, future financing activities, and market opportunity. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including but not limited to: the outcome of ongoing and planned clinical trials; regulatory review and approval timelines by the U.S. Food and Drug Administration; the availability of reimbursement from government and private payers; the company’s ability to raise additional capital on acceptable terms or at all; competitive developments in the wound care and regenerative medicine markets; and broader macroeconomic and market conditions. These forward-looking statements speak only as of the date of this release. Omeza undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.

SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Sagimet’s prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil, who will continue to support the Company as an external scientific advisor, has retired effective April 20, 2026. “We are delighted to welcome Dr. Andreas Grauer to our executive leadership team as Chief Medical Officer. Dr. Grauer has an extensive track record in leading clinical development and medical affairs in global pharmaceutical organizations as well as an impressive academic career. His expertise and insights will be key as we advance our FASN inhibitors in clinical development,” said David Happel, Chief Executive Officer of Sagimet. “We also want to thank Dr. Eduardo Martins for his many significant contributions to advancing Sagimet’s FASN inhibitor pipeline over his five-year tenure, as he retires and transitions into his new external advisor role.” “I am honored to join Sagimet to lead the clinical development of the Company’s FASN inhibitor drug candidates,” Dr. Grauer commented. “It is an exciting time to join Sagimet, and I look forward to leveraging my experience in drug development and medicals affairs to bring innovative therapeutics to underserved patients.” Dr. Grauer brings more than two decades of global biopharmaceutical leadership experience, with deep expertise spanning clinical development, medical affairs, and regulatory strategy across multiple therapeutic areas. He most recently served as Chief Medical Officer at Omeros Corporation (NASDAQ: OMER), where he led all clinical, safety, and medical functions advancing a pipeline of complement-targeted therapies in hematologic and immune-mediated diseases. Prior to Omeros, Dr. Grauer held Chief Medical Officer roles at Federation Bio and Corcept Therapeutics Incorporated, where he built and led global development organizations, advanced first-in-class programs into the clinic, and drove regulatory interactions across the U.S., Europe, and other major markets. Earlier in his career, Dr. Grauer spent over a decade at Amgen, Inc. in senior global development leadership roles, including Therapeutic Area Head for Bone, Nephrology, and Inflammation, with responsibility for late-stage programs, global filings, and lifecycle strategy for multiple blockbuster assets. He began his industry career at Procter & Gamble Pharmaceuticals in medical affairs. In addition to his industry experience, Dr. Grauer is a physician-scientist with over 120 peer-reviewed publications, including in leading journals such as The New England Journal of Medicine and The Lancet , and continues to serve as an Associate Professor of Medicine at the University of Heidelberg Medical School, Germany, where he received his MD and also completed his clinical training in internal medicine and endocrinology. Inducement Equity Grant In connection with Dr. Grauer joining Sagimet, the Compensation Committee of Sagimet’s Board of Directors approved the grant of an inducement stock option to be granted on April 20, 2026 to purchase a number of shares of the Company’s Series A common stock with a total fair market value of $1,340,000 as determined based on the Black Scholes value on April 20, 2026. The option award was granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of Dr. Grauer’s employment compensation and was granted as an inducement material to his acceptance of employment with Sagimet. The options have an exercise price equal to the closing price of Sagimet’s Series A common stock as reported by the Nasdaq Global Market on April 20, 2026. The options have a ten-year term and vest over four years, with 25% of the number of shares underlying each stock option vesting on the one-year anniversary of the applicable vesting commencement date (based on the employee’s employment commencement date) and the remaining shares vesting monthly over 36 months thereafter, subject to the individual’s continued service with Sagimet through the applicable vesting dates. About Sagimet Biosciences Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. Denifanstat, an oral, once-daily pill, met all primary endpoints in its Phase 2b FASCINATE-2 clinical trial in MASH, as well as all primary and secondary endpoints in Sagimet’s license partner for China’s Phase 3 clinical trial in moderate-to-severe acne. A combination of denifanstat and resmetirom was tested in a Phase 1 PK clinical trial and is planned to be developed for patients with MASH cirrhosis (F4). TVB-3567, a second oral FASN inhibitor which is planned to be developed for acne, is currently being tested in a Phase 1 first-in-human clinical trial. For additional information about Sagimet, please visit . Forward-Looking Statements This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding: the expected timing of the presentation of data from ongoing clinical trials, Sagimet’s clinical development plans and related timelines and anticipated development milestones, Sagimet’s cash and financial resources and expected cash runway are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet’s control, including, among others: the clinical development and therapeutic potential of denifanstat, TVB-3567 or any other drug candidates or combination therapies developed by Sagimet; Sagimet’s ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines; Sagimet’s relationship with Ascletis Bioscience Co. Ltd., and the success of its development efforts for denifanstat; the accuracy of Sagimet’s estimates regarding its capital requirements; and Sagimet’s ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of Sagimet’s most recent filings with the Securities and Exchange Commission and available at . You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Investor Contact: Joyce Allaire LifeSci Advisors JAllaire@LifeSciAdvisors.com Media Contact: Maggie Whitney LifeSci Communications mwhitney@lifescicomms.com